Hyloris Obtains Access to a EUR 6 Million Financing Package as an Extra Liquidity Buffer to Fund Future Growth

- **A non-dilutive EUR 5 million senior secured revolving credit facility from Belfius as an extra liquidity buffer, supported by guarantees from the CEO and Wallonie Entreprendre**
- **A EUR 1 million subordinated secured convertible bond to be subscribed for by a company controlled by CEO Stijn Van Rompay**
- **Waiver of prior support arrangements from CEO Stijn Van Rompay, upon completion of the financing structure**

Liège, Belgium – 28 October 2026 – 06:30 PM CET – Regulated information – Inside information – Hyloris Pharmaceuticals SA ("Hyloris") (Euronext Brussels: HYL) today announces that it has obtained a EUR 6 million financing package to enhance its financial flexibility and support continued growth: a non-dilutive EUR 5 million senior secured revolving credit facility from Belfius Bank SA/NV ("Belfius"), complemented by a EUR 1 million subordinated secured convertible bond to be subscribed for by a company controlled by CEO Stijn Van Rompay. The Belfius facility is supported by guarantees from the CEO and Wallonie Entreprendre, and will mature on 31 October 2028. Upon the successful completion of this financing structure, Hyloris has agreed to waive certain prior support arrangements from CEO Stijn Van Rompay.

These arrangements provide Hyloris with additional financing flexibility towards the future, and an additional liquidity buffer without requiring immediate equity issuance.

Financing structure. Hyloris has entered into a EUR 5 million senior secured revolving credit facility from Belfius, on market terms, available for working capital and general corporate purposes. The facility is supported by a EUR 1 million guarantee and a letter of intent (to ensure that Hyloris has sufficient cash to allow it to meet its obligations under the facility) provided by CEO Stijn Van Rompay, and a EUR 1.5 million guarantee provided by Wallonie Entreprendre, and is complemented by the CEO's EUR 1 million subordinated secured convertible bond.

CEO subordinated secured convertible bond. The EUR 1 million bond carries a 3-year tenor as from its effective subscription and issuance and a 5% p.a. cash coupon, and is fully convertible at a 33.33% premium to the volume-weighted average price (VWAP) of the Hyloris share over the three consecutive trading days starting on the first trading day following this press release. The resulting conversion price will be disclosed separately. The bondholders benefit from a second ranking pledge on Hyloris' business and on the shares it holds in Hyloris Developments SA/NV.

The bonds will be issued upon Hyloris' first request, at the latest by the 15th day after the publication of the 2026 full year results, and will have to be fully issued and subscribed for EUR 1 million as a condition precedent to any drawdown under the EUR 5 million senior secured revolving credit facility from Belfius.

The bonds can be converted by the bondholders after the expiry of a lock-up period of 12 months as from the effective issuance.

Governance. As a related-party transaction, the terms of the convertible bond, the guarantee, the letter of intent and the waiver of the prior support arrangements were reviewed by a committee of

independent directors under Article 7:97 of the Belgian Code of Companies and Associations and approved by the board of directors.

More detailed information on the related party transaction is set out in the public announcement pursuant to Article 7:97, §4/1 of the Belgian Code of Companies and Associations annexed to this press release.

Rationale. This financing further strengthens the company's balance sheet and provides additional headroom to support execution of its strategy, with financial flexibility to fund growth on terms that are predominantly non-dilutive.

Stijn Van Rompay, CEO of Hyloris, commented: *"I'm pleased we have now effectively obtained access to EUR 6 million in funding. This provides us with additional financial flexibility, while we continue to roll-out our portfolio and advance licensing discussions that we expect can generate upfront payments."*

About Hyloris Pharmaceuticals

Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation and repurposing to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payers. The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. Hyloris has a broad development portfolio including more than 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved and commercialized in the U.S.: Podofilox Gel and Tranexamic Acid RTU. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. ***Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide***. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (XBR: HYL) with about 54 people across 13 nationalities, targeting time-to-market of 7 years at an average cost of EUR 7 million per product (non-inflation adjusted).

For more information, visit www.hyloris.com and follow-us on LinkedIn.

Hyloris Pharmaceuticals contacts:

Ann De Jaeger, CLO
legal representative of Impact WITH Empathy BV
Ann.dejaeger@hyloris.com
32 (0)475 20 13 44 - 32 (0)4 346 02 07

Stijn Van Rompay, CEO
legal representative of SVR Management BV
stijn.vanrompay@hyloris.com
32 (0)4 346 02 07

Christophe Maréchal, CFO
legal representative of CMM&C srl
Christophe.Marechal@hyloris.com
32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and no securities may be offered or sold in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Public announcement pursuant to Article 7:97, §4/1 of the Belgian Code of Companies and Associations regarding a transaction with related parties

The main aspects of the transaction can be summarised as follows:

- EUR 1 million subordinated secured convertible bond, to be subscribed for by SVR Invest SRL/BV, a company controlled by Stijn Van Rompay:
    - Non-listed convertible bonds, in registered form, each with a denomination of EUR 100,000
    - Effective subscription and issuance upon Hyloris' first request, at the latest by the 15th day after the publication of the 2026 full year results
    - Fully subordinated to the EUR 5,000,000 Belfius senior facility
    - Second ranking pledge on Hyloris' business and on the shares Hyloris holds in Hyloris Developments SA/NV
    - Tenor of 3 years as from effective subscription and issuance
    - Cash coupon of 5.00% per annum
    - Voluntary conversion after the expiry of a lock-up period of 12 months as from the effective issuance; no mandatory conversion
    - Conversion at a 33.33% premium to the volume-weighted average price (VWAP) of the Hyloris share over the three trading days starting on the first trading day following the announcement of the principle of the issuance of convertible bonds (before market opening).
    - Each new share to be issued upon conversion shall have the same rights and benefits as the existing and outstanding shares at the moment of their issue
    - Early mandatory repayment upon customary events of default and in the event of a change of control over Hyloris (subject to shareholder approval; if no shareholder approval is obtained, the cash coupon will increase with one percentage point per annum)
    - Bonds are freely transferable after the expiry of a 6 months' lock-up as from the effective issuance (limited exceptions to the lock-up apply)
- EUR 1 million guarantee, granted by Stijn Van Rompay:
    - Guaranteeing the obligations of Hyloris under the EUR 5,000,000 Belfius senior facility
    - Fee of 2.00% per annum on the outstanding guaranteed amount
- Letter of intent, granted by SVR Management SRL/BV, to ensure that Hyloris has sufficient cash to allow it to meet its obligations under the EUR 5,000,000 Belfius senior facility
- Waiver of the prior support arrangements from Stijn Van Rompay for a total amount of EUR 6,000,000.

More information on the convertible bond, as well as its terms and conditions, can be found on the website of Hyloris: www.hyloris.com.

SVR Management SRL/BV is a director and the CEO of Hyloris. Stijn Van Rompay exercises a "significant influence" over Hyloris and he is the permanent representative of SVR Management SRL/BV. SVR Invest SRL/BV is controlled by Stijn Van Rompay. Therefore, Stijn Van Rompay, SVR

Management SRL/BV and SVR Invest SRL/BV are "related parties" of Hyloris within the meaning of Article 7:97 of the Belgian Code of Companies and Associations. As a result, the board of directors of Hyloris has requested a committee composed of three independent directors of Hyloris to issue an opinion on the transaction.

The committee of independent directors concluded as follows: "*After having reviewed the financial and legal terms and conditions of the Transaction, the Committee is of the unanimous view that the Transaction is in the best interest of the Company and its shareholders, considering the strategy of the Company, the rationale of the Transaction and the possible benefits that may be derived from it. The Committee also believes that the Transaction is unlikely to result in adverse consequences that would not be compensated for by benefits for the Company.*".

The board of directors of Hyloris did not deviate from the conclusion of the committee of independent directors.

On 28 October 2026, the board of directors of Hyloris approved the transaction and the execution of the related documents. The effective issuance of the bonds will take place upon Hyloris' first request, at the latest by the 15th day after the publication of the 2026 full year results.

Finally, the statutory auditor of Hyloris concluded as follows: "*Based on our assessment, we have not identified any facts that lead us to believe that the financial and accounting data included in the opinion of the committee of independent directors dated 27 October 2026 and in the minutes of the board of directors dated 28 October 2026, justifying the proposed transaction, contain any material inconsistencies with the information available to us in the context of our engagement.*".

For further information, please contact Ann De Jaeger, CLO, Ann.dejaeger@hyloris.com.